

Investment Opportunity in a Next Generation Blockbuster Cancer Drug

Optimising cancer therapeutics to improve patient treatment outcomes and quality of life

FIVEPHUSION

Founded by oncologists to develop more effective therapies for their patients, FivepHusion's lead asset Deflexifol® is an advanced, next-generation anti-cancer drug. With significantly enhanced efficacy for a range of cancers, FivepHusion's goal is to commercialise Deflexifol® to be adopted as the global 'gold standard' for the treatment of various solid tumours, with potential peak annual revenues of US\$1.8B.

Initial patient trials confirm the potential of Deflexifol® as a superior treatment option for its lead indication, metastatic colorectal cancer (US\$13B market), plus a range of other cancers including pancreatic, head & neck, brain and gastric cancers (>8M new cases annually).

FivepHusion is raising pre-IPO capital now with plans to IPO in the first half of 2026 to fund progression of Deflexifol® to registration trials in late 2026 / early 2027.

THE PROBLEM WE SOLVE

For decades, the backbone treatment for hard-to-treat cancers has been the administration of 5-fluorouracil (5-FU) with leucovorin (LV), a drug that enhances 5-FU anti-cancer activity. These drugs are currently chemically incompatible and are thus administered serially rather than simultaneously, leading to sub-optimal co-exposure and limited efficacy.

In treating metastatic colorectal cancer (mCRC), only ~55% of patients respond to best clinical practice, with a typical life expectancy of 20-30 months.

OUR SOLUTION

Deflexifol® is an innovative 'All-in-One' 5-FU and LV co-formulation that addresses the significant limitations with current standard of care treatment, offering a "best in class" therapy with greater safety, tolerability and superior efficacy. FivepHusion trials and five independent clinical trials point towards significant improvements to patient response rates and life expectancy. Deflexifol® optimises 5-FU/LV administration and synergy, offering a 10-fold increase in 5-FU+LV co-exposure alongside greater patient tolerability allowing for a 40+% increase in 5-FU dosing, which may further improve patient outcomes.



INVESTMENT HIGHLIGHTS

Deflexifol® has the potential to become a global 'blockbuster' drug, representing a compelling investment opportunity, de-risked through the optimised delivery of proven cancer therapies already utilised extensively across cancer indications.

- Deflexifol® is at advanced clinical stage and positioned to become the new 'go-to' standard of care for the treatment of mCRC patients.
- Lower developmental and regulatory risks for Deflexifol® as an optimised formulation, particularly in comparison to a typical New Molecular Entity.
- FivepHusion has established strategic collaborations that provide access to global expertise, resources, capabilities and technology to accelerate Deflexifol® development, and de-risk its commercialisation:
 - Pfizer CentreOne (Melbourne): manufacture of Deflexifol®
 - Syneos Health (Global): clinical development and commercialisation
 - Allarity Therapeutics (USA/DK): precision oncology applications



- Commercial interest from multiple pharma companies. Exciting precedents for Deflexifol® to attract lucrative licensing / M&A deals.
- Granted composition of matter IP in the US and other major markets, with a patent pipeline and market protection to >2045.
- Peak sales potential ~US\$1B (for mCRC only), growing to ~US\$1.8B when used across other applicable cancers.
- Limited competition – no other novel treatments demonstrate a significant potential to displace 5-FU in the first-line treatment of solid tumours.
- Rapid clinical adoption – leading oncologists confirm that on a successful phase III result Deflexifol® would be widely adopted within 2 years of launch.
- Premium drug pricing expected by payers due to next generation superior safety and efficacy for cancers with limited treatment options.
- An exceptional board and management team supported by globally experienced clinical, regulatory, manufacturing and commercial teams. The FivepHusion Board comprises of deep drug development and commercial expertise, including Dr Bill Ketelbey (ex. SVP Pfizer) and Mr Iain Ross (Chairman, Silence Therapeutics (NASDAQ: SLN)).
- Significant near-term liquidity through a planned H1 2026 IPO, with short term catalysts leading to heightened pharma partnering interest.

THE MARKET

Colorectal cancer is the third most diagnosed cancer globally. Up to a third of these patients are diagnosed metastatic (Stage IV), a US\$13B market. ~95% of mCRC patients are treated with 5-FU and LV, which are administered sub-optimally. Following potential commercial launch as early as 2029, the progressive global adoption of Deflexifol® as a superior mCRC treatment regime is anticipated to deliver sales revenues approaching ~US\$1B within five years. These projected revenues will be supplemented as applications of Deflexifol® in the treatment of additional cancer indications are approved, reaching projected peak sales of US\$1.8B p.a.

PIPELINE OPPORTUNITIES


- Potential for Deflexifol® approval and use in all cancers currently treated with 5-FU, e.g., pancreatic, head & neck, breast and gastric cancers.
- The unique attributes of Deflexifol® are being leveraged to investigate new 5-FU/LV applications, including the treatment of paediatric brain cancers (US\$1.8B market). A successfully completed phase 1b study has confirmed a safe and tolerable Deflexifol® dose in paediatric brain cancer patients.
- The ResectAssist™ drug delivery platform, an innovative technology enabling high-dose, targeted administration of a diverse range of approved and investigational drugs directly into tumours with high unmet medical needs, with an initial focus on pancreatic cancer (~US\$7B market in 2030).

DE-RISKED INVESTMENT

FivepHusion is currently undertaking a pre-IPO capital raise with plans for an IPO in H1 2026 to progress Deflexifol® development towards registration trials.

USE OF PROCEEDS:

- Planning for an IPO.
- Phase Ib mCRC & paediatric brain cancer trials.
- Scale up GMP manufacturing at Pfizer CentreOne.
- Gaining FDA IND approvals - both indications.
- Development of pipeline opportunities including new indications treatable by Deflexifol® and the ResectAssist™ platform technology.
- Pharma partnering and business development.



Detsamma Investments Pty Ltd trading as "FivepHusion"

Dr Christian Toouli, CEO & MD, c.toouli@fivephusion.com

Fivephusion.com

